Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP841321.RAsL3DZOeUjsipoxLu72f16PkrvycGauQmCnqr65eRo6E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP841321.RAsL3DZOeUjsipoxLu72f16PkrvycGauQmCnqr65eRo6E130_assertion type Assertion NP841321.RAsL3DZOeUjsipoxLu72f16PkrvycGauQmCnqr65eRo6E130_head.
- NP841321.RAsL3DZOeUjsipoxLu72f16PkrvycGauQmCnqr65eRo6E130_assertion description "[Of the 31 patients in remission at 12 months post-HCT, disease-free survival was 86% in patients with MRD <10(-4) and 20% in those with MRD ?10(-4) (relapse hazard ratio (HR) 9.0; 95% confidence interval (CI) 2.5-32; P<0.0001), with median follow-up of 36 months.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP841321.RAsL3DZOeUjsipoxLu72f16PkrvycGauQmCnqr65eRo6E130_provenance.
- NP841321.RAsL3DZOeUjsipoxLu72f16PkrvycGauQmCnqr65eRo6E130_assertion evidence source_evidence_literature NP841321.RAsL3DZOeUjsipoxLu72f16PkrvycGauQmCnqr65eRo6E130_provenance.
- NP841321.RAsL3DZOeUjsipoxLu72f16PkrvycGauQmCnqr65eRo6E130_assertion SIO_000772 23419792 NP841321.RAsL3DZOeUjsipoxLu72f16PkrvycGauQmCnqr65eRo6E130_provenance.
- NP841321.RAsL3DZOeUjsipoxLu72f16PkrvycGauQmCnqr65eRo6E130_assertion wasDerivedFrom befree-20150227 NP841321.RAsL3DZOeUjsipoxLu72f16PkrvycGauQmCnqr65eRo6E130_provenance.
- NP841321.RAsL3DZOeUjsipoxLu72f16PkrvycGauQmCnqr65eRo6E130_assertion wasGeneratedBy ECO_0000203 NP841321.RAsL3DZOeUjsipoxLu72f16PkrvycGauQmCnqr65eRo6E130_provenance.